WASHINGTON, DC / ACCESSWIRE / June 17, 2024 / FindMyClinicalTrial Inc. (FMCT), a digital health startup company building patient engagement and recruitment solutions for clinical trials, today announced a know-how agreement with Mayo Clinic to continue and finalize the development of FMCT’s clinical trial platforms for patients, health centers, and research sites.
Clinical trials are crucial for advancing medical knowledge and bringing new treatments to patients. However, patient recruitment and engagement remain major challenges, with up to 80% of trials delayed or terminated due to enrollment difficulties. FMCT takes a community-driven approach by building its software around facilitating engagement between trial teams, health centers, and patient communities.
“We are excited to collaborate with Mayo Clinic,” said Killian Lozach, CEO of FMCT. “Together, we aim to transform how patients connect with and participate in clinical trials by empowering them with education, community support, and seamless digital experiences.”
The collaboration aims to leverage Mayo Clinic’s extensive clinical trial expertise and FMCT’s cutting-edge technology to develop a patient-centric platform that streamlines recruitment, enhances engagement, and improves retention throughout the clinical trial journey.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
Contact Information
Emma Briggs
Vice President – Strategic Alliances
emma.briggs@findmyclinicaltrial.org
Killian Lozach
CEO & Founder
killian.lozach@findmyclinicaltrial.org
8583365157
SOURCE: FindMyClinicalTrial Inc.
View the original press release on newswire.com.
View the original press release on accesswire.com
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…
